CLDX Latest News, Press Relases and Analysis

All

Press Releases

19 days ago - By: Celldex Therapeutics, Inc.

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

19 days ago - By: Celldex Therapeutics, Inc.

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

19 days ago - By: Benzinga - Mentions: AIV TGNA ALB FRHC ...

Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday?

2 months ago - By: Benzinga

Analyst Expectations For Celldex Therapeutics's Future

19 days ago - By: Celldex Therapeutics, Inc.

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

19 days ago - By: Celldex Therapeutics, Inc.

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

22 days ago - By: Celldex Therapeutics, Inc.

Celldex to Present at Upcoming Investor Conferences

22 days ago - By: Celldex Therapeutics, Inc.

Celldex to Present at Upcoming Investor Conferences

23 days ago - By: Celldex Therapeutics, Inc.

Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study

23 days ago - By: Celldex Therapeutics, Inc.

Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients

a month ago - By: Celldex Therapeutics, Inc.

Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition

a month ago - By: Celldex Therapeutics, Inc.

Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition

3 months ago - By: Stocktwits

Why Are Celldex Shares Tumbling After Hours?

2 months ago - By: Celldex Therapeutics, Inc.

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

2 months ago - By: Celldex Therapeutics, Inc.

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

3 months ago - By: Celldex Therapeutics, Inc.

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

3 months ago - By: Celldex Therapeutics, Inc.

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

3 months ago - By: Celldex Therapeutics, Inc.

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

3 months ago - By: Celldex Therapeutics, Inc.

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

4 months ago - By: Zacks Investment Research - Mentions: YMAB

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: Celldex Therapeutics, Inc.

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Celldex Therapeutics, Inc.

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

6 months ago - By: Stocktwits

Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded

6 months ago - By: Celldex Therapeutics, Inc.

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

6 months ago - By: Celldex Therapeutics, Inc.

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

CELLDEX THERAPEUTICS INC (CLDX) Stock News

CLDX Latest News, Press Relases and Analysis